![Mark Davies](https://profiles-cardiff.imgix.net/attachments/7724?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Trosolwg
Rwy'n cynnal ymchwil drosiadol gyda'r nod o wella triniaethau ar gyfer canser a syndromau rhagdybiaeth tiwmor etifeddol. Rwyf wedi fy achredu'n ddeuol mewn oncoleg feddygol a geneteg glinigol. Mae fy ngwaith clinigol yn canolbwyntio ar drin canser y fron a phlant sydd â rhagdueddiad genetig i ganser.
Mae fy ymchwil yn canolbwyntio ar:
-
Targedu'r llwybr signalau mTOR – Yn flaenorol, arweiniais un o'r treialon clinigol cyntaf gan ddangos bod atalyddion mTOR yn driniaeth effeithiol ar gyfer y cyflwr genetig sglerosis tiwbaidd. Ar hyn o bryd, fel rhan o'r grŵp signalau mTOR, rydym yn nodi triniaethau newydd sy'n manteisio ar wendidau therapiwtig sy'n deillio o orfywiogrwydd mTOR.
-
Datblygu dulliau newydd o drin canser – rwy'n archwilio tiwmorau fel ecosystemau cymhleth ac yn cymhwyso cysyniadau ecolegol fel cystadleuaeth ac ysglyfaethu i nodi strategaethau therapiwtig newydd.
-
Prif ffrydio genomeg i oncoleg – rwy'n gweithio ar integreiddio data genomig i oncoleg glinigol i wella canlyniadau cleifion a phersonoli triniaeth canser.
Cyhoeddiad
2026
- Ćavar Pavić, J. et al., 2026. Challenges in identifying paediatric cancer predisposition syndromes: international SCOPE survey and SIOPE expert consensus recommendations. European Journal of Human Genetics 34 , pp.1374-1383. (10.1038/s41431-026-02040-x)
- Gevertz, J. L. et al., 2026. Delaying cancer progression by integrating toxicity constraints in a model of adaptive therapy. npj Systems Biology and Applications 12 11. (10.1038/s41540-025-00635-6)
2025
- Burton, J. R. et al., 2025. Value-based healthcare in practice: IDEATE, a collaboration to design and test an outcomes-based agreement for a medicine in Wales. PharmacoEconomics 43 (2), pp.191-207. (10.1007/s40273-024-01445-0)
- Alcock, A. et al., 2025. Incidental findings in surveillence of paediatric Li Fraumeni patients - A single centre experience. Rare 3 100067. (10.1016/j.rare.2025.100067)
2024
- Abraham, J. E. et al., 2024. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature 629 , pp.1142–1148. (10.1038/s41586-024-07384-2)
2023
- Munir, A. et al., 2023. A 10 year service evaluation of the survival of 439 patients with early oestrogen receptor positive breast cancer who underwent initial OncotypeDX ® testing to guide adjuvant chemotherapy decisions. Cancer Treatment and Research Communications 34 100671. (10.1016/j.ctarc.2022.100671)
- Farook, M. R. et al., 2023. Loss of mitochondrial pyruvate carrier 1 supports proline-dependent proliferation and collagen biosynthesis in ovarian cancer. Molecular Metabolism 81 101900. (10.1016/j.molmet.2024.101900)
2022
- Champion, J. D. et al. 2022. Drug inhibition of redox factor-1 restores hypoxia-driven changes in tuberous sclerosis complex 2 deficient cells. Cancers 14 (24) 6195. (10.3390/cancers14246195)
- Mateo, J. et al., 2022. Delivering precision oncology to patients with cancer. Nature Medicine 28 (4), pp.658–665. (10.1038/s41591-022-01717-2)
- Malorni, L. et al., 2022. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. European Journal of Cancer 164 , pp.39-51. (10.1016/j.ejca.2021.12.030)
2021
- El Badri, S. et al., 2021. Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study. The Breast 60 , pp.199-205. (10.1016/j.breast.2021.10.010)
2019
- Holborow, A. et al., 2019. Machine learning methods in predicting chemotherapy-induced neutropenia in oncology patients using clinical data. Clinical Medicine 19 (3), pp.s89-s90. (10.7861/clinmedicine.19-3s-s89)
2018
- Johnson, C. E. et al. 2018. Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir−bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death. Oncogene 37 , pp.5913-5925. (10.1038/s41388-018-0381-2)
- McCann, H. et al. 2018. Energy stress-mediated cytotoxicity in tuberous sclerosis complex 2-deficient cells with nelfinavir and mefloquine treatment. Cancers 10 (10) 375. (10.3390/cancers10100375)
2013
- Murray, A. J. and Davies, D. M. 2013. The genetics of breast cancer. Surgery (Oxford) 31 (1), pp.1-3. (10.1016/j.mpsur.2012.10.019)
2010
- Davies, D. M. and Sampson, J. R. 2010. Small-molecule signal-transduction inhibitors: targeted therapeutic agents for single-gene disorders. Journal of Medical Genetics 47 (3), pp.145-149. (10.1136/jmg.2008.064113)
2009
- Davies, M. 2009. Colorectal cancer and GI polyps: when to refer patients for genetic assessment. Gastrointestinal Nursing 7 (8), pp.36-42. (10.12968/gasn.2009.7.8.44748)
2007
- Upadhyaya, M. et al. 2007. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. The American Journal of Human Genetics 80 (1), pp.140-151. (10.1086/510781)
Articles
- Ćavar Pavić, J. et al., 2026. Challenges in identifying paediatric cancer predisposition syndromes: international SCOPE survey and SIOPE expert consensus recommendations. European Journal of Human Genetics 34 , pp.1374-1383. (10.1038/s41431-026-02040-x)
- Gevertz, J. L. et al., 2026. Delaying cancer progression by integrating toxicity constraints in a model of adaptive therapy. npj Systems Biology and Applications 12 11. (10.1038/s41540-025-00635-6)
- Burton, J. R. et al., 2025. Value-based healthcare in practice: IDEATE, a collaboration to design and test an outcomes-based agreement for a medicine in Wales. PharmacoEconomics 43 (2), pp.191-207. (10.1007/s40273-024-01445-0)
- Alcock, A. et al., 2025. Incidental findings in surveillence of paediatric Li Fraumeni patients - A single centre experience. Rare 3 100067. (10.1016/j.rare.2025.100067)
- Abraham, J. E. et al., 2024. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature 629 , pp.1142–1148. (10.1038/s41586-024-07384-2)
- Munir, A. et al., 2023. A 10 year service evaluation of the survival of 439 patients with early oestrogen receptor positive breast cancer who underwent initial OncotypeDX ® testing to guide adjuvant chemotherapy decisions. Cancer Treatment and Research Communications 34 100671. (10.1016/j.ctarc.2022.100671)
- Farook, M. R. et al., 2023. Loss of mitochondrial pyruvate carrier 1 supports proline-dependent proliferation and collagen biosynthesis in ovarian cancer. Molecular Metabolism 81 101900. (10.1016/j.molmet.2024.101900)
- Champion, J. D. et al. 2022. Drug inhibition of redox factor-1 restores hypoxia-driven changes in tuberous sclerosis complex 2 deficient cells. Cancers 14 (24) 6195. (10.3390/cancers14246195)
- Mateo, J. et al., 2022. Delivering precision oncology to patients with cancer. Nature Medicine 28 (4), pp.658–665. (10.1038/s41591-022-01717-2)
- Malorni, L. et al., 2022. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. European Journal of Cancer 164 , pp.39-51. (10.1016/j.ejca.2021.12.030)
- El Badri, S. et al., 2021. Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study. The Breast 60 , pp.199-205. (10.1016/j.breast.2021.10.010)
- Holborow, A. et al., 2019. Machine learning methods in predicting chemotherapy-induced neutropenia in oncology patients using clinical data. Clinical Medicine 19 (3), pp.s89-s90. (10.7861/clinmedicine.19-3s-s89)
- Johnson, C. E. et al. 2018. Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir−bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death. Oncogene 37 , pp.5913-5925. (10.1038/s41388-018-0381-2)
- McCann, H. et al. 2018. Energy stress-mediated cytotoxicity in tuberous sclerosis complex 2-deficient cells with nelfinavir and mefloquine treatment. Cancers 10 (10) 375. (10.3390/cancers10100375)
- Murray, A. J. and Davies, D. M. 2013. The genetics of breast cancer. Surgery (Oxford) 31 (1), pp.1-3. (10.1016/j.mpsur.2012.10.019)
- Davies, D. M. and Sampson, J. R. 2010. Small-molecule signal-transduction inhibitors: targeted therapeutic agents for single-gene disorders. Journal of Medical Genetics 47 (3), pp.145-149. (10.1136/jmg.2008.064113)
- Davies, M. 2009. Colorectal cancer and GI polyps: when to refer patients for genetic assessment. Gastrointestinal Nursing 7 (8), pp.36-42. (10.12968/gasn.2009.7.8.44748)
- Upadhyaya, M. et al. 2007. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. The American Journal of Human Genetics 80 (1), pp.140-151. (10.1086/510781)
Ymchwil
Mae fy ymchwil yn canolbwyntio ar dri maes allweddol gyda'r nod o wella triniaeth canser a chanlyniadau cleifion:
-
Targedu'r Llwybr mTOR – mae gen i ddiddordeb hirsefydlog yn y llwybr signalau mTOR a'i rôl mewn tumorigenesis, yn enwedig mewn syndromau rhagdybiaeth tiwmor fel cyfadeilad sglerosis tiwbaidd (TSC). Cyfrannodd fy ngwaith at y treialon clinigol cyntaf sy'n dangos effeithiolrwydd atalyddion mTOR mewn tiwmorau sy'n gysylltiedig â TSC, gan arwain at newid byd-eang mewn ymarfer clinigol. Rwy'n parhau i archwilio gwendidau therapiwtig sy'n deillio o orfywiogrwydd mTOR, gyda'r nod o nodi strategaethau triniaeth newydd.
-
Trin Canser fel Ecosystem – Mae fy ymchwil yn cymryd persbectif ecolegol ar ganser, gan edrych ar diwmorau fel ecosystemau deinamig wedi'u siapio gan bwysau esblygol. Rwy'n ymchwilio i sut mae egwyddorion ecolegol fel cystadleuaeth, ysglyfaethu, ac argaeledd adnoddau yn dylanwadu ar gynnydd tiwmor ac ymateb i therapi. Mae'r dull hwn yn llywio strategaethau therapiwtig newydd, gan gynnwys therapi addasol, sy'n ceisio rheoli esblygiad tiwmor a gwrthsefyll cyffuriau.
-
Prif ffrydio genomeg i mewn i oncoleg – rwyf wedi ymrwymo i integreiddio data genomig i arfer oncoleg arferol i bersonoli triniaeth a gwella canlyniadau cleifion. Mae hyn yn cynnwys ymdrechion blaenllaw i sefydlu gwasanaethau clinigol sy'n cael eu gyrru gan genomeg, cyfrannu at ganllawiau cenedlaethol ar asesu risg genetig, a chymryd rhan mewn astudiaethau genomig ar raddfa fawr i wella cymhwysiad clinigol dilyniannu genomau mewn diagnosis a thriniaeth canser
Bywgraffiad
Ar ôl astudio Biocemeg ym Mhrifysgol Rhydychen, cwblheais radd feddygol ym Mhrifysgol Caerdydd. Yn dilyn hynny, cynhaliais hyfforddiant eang mewn meddygaeth oedolion a phediatreg yn Ne Cymru, Rhydychen a Birmingham, gan ennill achrediad deuol mewn oncoleg feddygol a geneteg glinigol.
Cwblheais PhD ym Mhrifysgol Caerdydd, gan ganolbwyntio ar dreial clinigol o atalyddion mTOR ar gyfer trin tiwmorau mewn cymhleth sglerosis tiwbaidd, sef syndrom rhagdybiaeth tiwmor. Cyfrannodd y gwaith hwn at newid byd-eang mewn ymarfer, gydag ataliad mTOR bellach yn un o brif gyfnodau wrth drin y cyflwr hwn.
Bûm yn gweithio fel ymgynghorydd GIG mewn oncoleg feddygol am dros ddegawd, gan drin cleifion â chanser y fron. Yn ystod y cyfnod hwn, sefydlais Glinig Sglerosis Tuberous Cymru Gyfan a Chlinig Rhagdybiaeth Canser Plant Cymru Gyfan. Yn 2022, cefais fy mhenodi'n Athro Anrhydeddus ym Mhrifysgol Abertawe.
Yn ddiweddar, cefais fy mhenodi'n Uwch-ddarlithydd Clinigol ym Mhrifysgol Caerdydd, Ymgynghorydd Anrhydeddus yn Ymddiriedolaeth GIG Felindre, ac Ymgynghorydd Anrhydeddus yng Ngwasanaeth Genomeg Meddygol Cymru Gyfan. Rwyf hefyd yn gwasanaethu fel Arweinydd Clinigol Rhwydwaith Canser Cymru ar gyfer Genomeg
Contact Details
Themâu ymchwil
Arbenigeddau
- Canser y fron
- Bioleg Celloedd
- Treialon clinigol
- Geneteg
- Genomeg